[go: up one dir, main page]

HUP9802300A2 - N-heteroaril-piridin-szulfonamid származékok, ezeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk - Google Patents

N-heteroaril-piridin-szulfonamid származékok, ezeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk

Info

Publication number
HUP9802300A2
HUP9802300A2 HU9802300A HUP9802300A HUP9802300A2 HU P9802300 A2 HUP9802300 A2 HU P9802300A2 HU 9802300 A HU9802300 A HU 9802300A HU P9802300 A HUP9802300 A HU P9802300A HU P9802300 A2 HUP9802300 A2 HU P9802300A2
Authority
HU
Hungary
Prior art keywords
atom
ring
tube
nitrogen
hydrogen
Prior art date
Application number
HU9802300A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Roger John Butlin
Roger James
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9802300(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9511507.7A external-priority patent/GB9511507D0/en
Priority claimed from GBGB9519666.3A external-priority patent/GB9519666D0/en
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of HUP9802300A2 publication Critical patent/HUP9802300A2/hu
Publication of HUP9802300A3 publication Critical patent/HUP9802300A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A találmány (I) általánős képletű vegyületekre, azők N-őxidjaira ésazők gyógyászatilag alkalmazható sóira vőnatkőzik - a képletben A1,A2, A3 és A4 egyike nitrőgénatőmőt, a többi pedig CH csőpőrtőt jelent,Ar adőtt esetben szűbsztitűált fenilcsőpőrtőt jelent, B1 halőgénatőmőtvagy alkil- vagy alkőxicsőpőrtőt jelent, m értéke 0, 1, 2 vagy 3, és(a) W és Y nitrőgénatőmőt, X és Z CH csőpőrtőt (ahől a Z csőpőrthőzszűbsztitűens kapcsőlódhat) és R1 hidrőgénatőmőt, halőgénatőmőt vagyalkil-, metőxi-, etőxi-, triflűőr-metil- vagy etinilcsőpőrtőt jelent,vagy (b) X és Y nitrőgénatőmőt, Z és W CH csőpőrtőt (ahől a Wcsőpőrthőz szűbsztitűens kapcsőlódhat) és R1 a hidrőgénatőmkivételével a fentiekben felsőrőlt csőpőrtőkat jelenti, vagy (c) W ésX nitrőgénatőmőt, Y és Z CH csőpőrtőt (ahől a Z csőpőrthőzszűbsztitűens kapcsőlódhat) és R1 a hidrőgénatőm kivételével afentiekben felsőrőlt csőpőrtőkat jelenti. A vegyületek endőtelinantagőnisták. (I) ŕ
HU9802300A 1995-06-07 1996-06-03 N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical compositions containing them, process for producing them and their use HUP9802300A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9511507.7A GB9511507D0 (en) 1995-06-07 1995-06-07 Heterocyclic compounds
GBGB9519666.3A GB9519666D0 (en) 1995-09-27 1995-09-27 Heterocyclic derivatives

Publications (2)

Publication Number Publication Date
HUP9802300A2 true HUP9802300A2 (hu) 1999-10-28
HUP9802300A3 HUP9802300A3 (en) 2002-02-28

Family

ID=26307176

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802300A HUP9802300A3 (en) 1995-06-07 1996-06-03 N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical compositions containing them, process for producing them and their use

Country Status (32)

Country Link
US (3) US5866568A (hu)
EP (1) EP0832082B1 (hu)
JP (1) JP3193058B2 (hu)
KR (1) KR100451523B1 (hu)
CN (1) CN1097051C (hu)
AR (1) AR003132A1 (hu)
AT (1) ATE209200T1 (hu)
AU (1) AU715041B2 (hu)
BR (1) BR9608611A (hu)
CA (1) CA2219742C (hu)
CZ (1) CZ289387B6 (hu)
DE (1) DE69617236T2 (hu)
DK (1) DK0832082T3 (hu)
EG (1) EG25227A (hu)
ES (1) ES2168487T3 (hu)
GE (1) GEP20053470B (hu)
HK (1) HK1005801A1 (hu)
HR (1) HRP960272B1 (hu)
HU (1) HUP9802300A3 (hu)
IL (1) IL122464A (hu)
MX (1) MX9709521A (hu)
MY (1) MY114926A (hu)
NO (1) NO314503B1 (hu)
NZ (1) NZ308619A (hu)
PL (1) PL187897B1 (hu)
PT (1) PT832082E (hu)
RU (1) RU2172738C2 (hu)
SK (1) SK282338B6 (hu)
TR (1) TR199701502T1 (hu)
TW (1) TW340845B (hu)
UA (1) UA58494C2 (hu)
WO (1) WO1996040681A1 (hu)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
SG87052A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Pinacol ester intermediates useful for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
GB9614804D0 (en) * 1996-07-15 1996-09-04 Chiroscience Ltd Resolution process
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
GB9704762D0 (en) * 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
WO1998049162A1 (en) 1997-04-28 1998-11-05 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP2002540088A (ja) 1999-03-19 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ビフェニルイソキサゾール・スルホンアミド化合物の製造法
US6448239B1 (en) * 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
DK1533311T3 (da) 1999-12-31 2007-09-17 Encysive Pharmaceuticals Inc Sulfonamider og derivater deraf, der modulerer aktiviteten af endothelin
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
KR100839512B1 (ko) * 2004-07-02 2008-06-19 주식회사 코오롱 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유
CA2586479A1 (en) 2004-11-12 2006-05-18 Trustees Of Tufts College Lipase inhibitors
US20070054325A1 (en) * 2005-04-14 2007-03-08 Reglia Materials and methods for screening modulators of neural regeneration
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
WO2007070432A2 (en) 2005-12-13 2007-06-21 Astrazeneca Ab Binding proteins specific for insulin-like growth factors and uses thereof
BRPI0708507A2 (pt) * 2006-03-03 2011-05-31 Torrent Pharmaceuticals Ltd Novos antagonistas de receptores de dupla ação (dara) para os receptores at1 eta
JP2009533420A (ja) * 2006-04-13 2009-09-17 アクテリオン ファーマシューティカルズ リミテッド 早期特発性肺線維症の治療
TW200820970A (en) * 2006-09-21 2008-05-16 Nicholas Piramal India Ltd Compounds for the treatment of metabolic disorders
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
AP2009005053A0 (en) 2007-05-03 2009-12-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
CA2701385A1 (en) * 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064
NZ589825A (en) 2008-06-19 2012-11-30 Takeda Pharmaceutical Heterocyclic compound and use thereof
ES2453474T3 (es) * 2009-02-06 2014-04-07 Nippon Shinyaku Co., Ltd. Derivados de aminopirazina y medicamento correspondiente
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
WO2020165226A1 (en) 2019-02-12 2020-08-20 The University Court Of The University Of Glasgow Microvascular angina
WO2021262998A1 (en) * 2020-06-25 2021-12-30 Wake Forest University Health Sciences Compounds for sensing reactive oxygen species and methods for using the same
CA3188345A1 (en) 2020-07-10 2022-01-13 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
TW202317555A (zh) * 2021-06-22 2023-05-01 日商亞克醫藥股份有限公司 化合物、內皮素a受體拮抗劑及醫藥組合物
US20240058331A1 (en) 2022-08-12 2024-02-22 Astrazeneca Ab Combination therapies for treatment of cirrhosis with portal hypertension
WO2024166009A1 (en) 2023-02-08 2024-08-15 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of high proteinuria chronic kidney disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0655708B2 (ja) * 1985-05-13 1994-07-27 三井東圧化学株式会社 スルホンアミド系化合物及び農業用殺菌剤
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH04503672A (ja) * 1989-02-27 1992-07-02 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 放射線増感剤としての新規なナフタレンスルホンアミド
TW270116B (hu) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (hu) * 1992-02-24 1994-06-01 Squibb & Sons Inc
WO1993021219A1 (en) * 1992-04-22 1993-10-28 Warner-Lambert Company Endothelin antagonists ii
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
WO1994002474A1 (en) * 1992-07-17 1994-02-03 Smithkline Beecham Corporation Endothelin receptor antagonists
TW287160B (hu) * 1992-12-10 1996-10-01 Hoffmann La Roche
EP0626174A3 (en) * 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Method and composition for the prophylaxis and / or treatment of underactive organs.
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
DE4426346A1 (de) * 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB2295616A (en) * 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
EE9700251A (et) * 1995-04-04 1998-04-15 Texas Biotechnology Corporation Tienüül-, furüül-, pürrolüül- ja bifenüülsulfoonamiidid ning nende derivaadid, mis moduleerivad endoteliini aktiivsust

Also Published As

Publication number Publication date
CA2219742C (en) 2007-01-16
IL122464A0 (en) 1998-09-15
US6258817B1 (en) 2001-07-10
ATE209200T1 (de) 2001-12-15
JPH11509175A (ja) 1999-08-17
EP0832082A1 (en) 1998-04-01
NO975700L (no) 1997-12-05
IL122464A (en) 2002-05-23
AU715041B2 (en) 2000-01-13
AR003132A1 (es) 1998-07-08
TW340845B (en) 1998-09-21
US5866568A (en) 1999-02-02
KR100451523B1 (ko) 2004-12-03
DK0832082T3 (da) 2002-05-21
HRP960272B1 (en) 2006-06-30
GEP20053470B (en) 2005-02-25
AU5840396A (en) 1996-12-30
MX9709521A (es) 1998-03-31
CN1192739A (zh) 1998-09-09
ES2168487T3 (es) 2002-06-16
JP3193058B2 (ja) 2001-07-30
PL187897B1 (pl) 2004-10-29
SK168097A3 (en) 1998-05-06
NZ308619A (en) 2000-01-28
RU2172738C2 (ru) 2001-08-27
DE69617236D1 (de) 2002-01-03
EG25227A (en) 2011-11-17
TR199701502T1 (xx) 1998-03-21
EP0832082B1 (en) 2001-11-21
HUP9802300A3 (en) 2002-02-28
US6060475A (en) 2000-05-09
CA2219742A1 (en) 1996-12-19
HRP960272A2 (en) 1997-08-31
CN1097051C (zh) 2002-12-25
BR9608611A (pt) 1999-05-11
SK282338B6 (sk) 2002-01-07
CZ289387B6 (cs) 2002-01-16
CZ388797A3 (cs) 1998-03-18
NO975700D0 (no) 1997-12-05
PT832082E (pt) 2002-04-29
KR19990022327A (ko) 1999-03-25
NO314503B1 (no) 2003-03-31
DE69617236T2 (de) 2002-07-11
UA58494C2 (uk) 2003-08-15
WO1996040681A1 (en) 1996-12-19
HK1005801A1 (en) 1999-01-29
MY114926A (en) 2003-02-28
PL324660A1 (en) 1998-06-08

Similar Documents

Publication Publication Date Title
HUP9802300A2 (hu) N-heteroaril-piridin-szulfonamid származékok, ezeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
HUP9902471A2 (hu) Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
ES8407025A1 (es) Un procedimiento para preparar derivados de nicotinamida.
BG100951A (en) Novel erythromycin derivatives, method for their preparation and their use as drugs
HUT59676A (en) Process for producing piperazinyl-alkyl-carbonyl derivatives of condensed heterocyclic compounds and pharmaceutical compositions containing them
AU648338B2 (en) Benzene, pyridine and pyrimidine derivatives
DE69227088D1 (de) Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln
NO995638L (no) Heterobicykliske forbindelser til fremstilling av pyridonkarboksylsyrederivater
MXPA02012569A (es) Ftalidas substituidas novedosas, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a las mismas.
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
HUP9901621A2 (hu) Protein kináz C inhibitor hatású alkil-oxi-amino szubsztituenst tartalmazó fluorenon-származékok, alkalmazásuk, intermedierjeik és ezek előállítása, valamint a vegyületeket tartalmazó gyógyászati készítmények
IE901314L (en) 2- substituted-n,n'-di(trimethoxybenzoyl)piperazines
HUP9601331A2 (hu) Piperazin- illetve homopiperazinszármazékok, eljárás előállításukra, és ilyen hatóanyagot tartalmazó gyógyászati készítmények
HUP9900739A2 (hu) Eljárás kinolinszármazékok előállítására és intermedierjeik
ES8504122A1 (es) Procedimiento para la obtencion de pirrolidinonas
ES8502700A1 (es) Procedimiento para la fabricacion de derivados de tetrahidrobenzotiazol.
NO982549L (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav
IL148590A0 (en) Alkaloid compounds and pharmaceutical compositions containing the same
EP0798304A4 (en) DRUGS AGAINST TRHOMBOCYTOPENIA
AU7641181A (en) N-phthalidyl-5-fluorouracil derivatives
DE3762341D1 (de) Chinolinderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende zubereitungen.
ES2056025A1 (es) Nuevos derivados de indol.
AU547599B2 (en) Tricyclic compounds
ATE4384T1 (de) Benzothiopyrano(2,3-c)pyridine und ihre saeureadditions-salze, ihre herstellung, ihre verwendung als arzneimittel und diese verbindungen enthaltende zusammensetzungen.
ES8300752A1 (es) "un procedimiento para la preparacion de derivados de n-ftalidil-5-fluorouracilo".

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished